A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.

Susana M CamposUrsula MatulonisSuzanne BerlinNeil HorowitzJoyce LiuCarolyn KrasnerLee HangCorrine ZarwanWilliam BarryTina ColellaChristen WhalenMelina ShoniChristine LundquistMichael J BirrerRichard Penson

Published in: International journal of clinical oncology (2022)

Combinatorial consolidation therapy with AE was associated with an improved progression-free survival in patients with Mullerian tumors.

Keyphrases

free survival
metastatic colorectal cancer
newly diagnosed
open label
advanced non small cell lung cancer
randomized controlled trial
phase ii study
clinical trial
radiation therapy
mesenchymal stem cells
cell therapy